Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Advertisement
A systemic review found that 21 of 90 randomized controlled trials for AML reported on patients' race and ethnicity.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The trial will evaluate the safety, optimal dosing, and CR rate and duration of Actimab-A, venetoclax, and ASTX-727 in AML.
Clinical development of AUTX-703 is planned to begin in the first quarter of 2025.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
The amended protocol includes reducing the size of the MIRACLE trial by approximately 10%.
A new study protocol plans for two phase III trials to evaluate the agent in intensive and nonintensive combinations for AML.
The first study on the efficacy and safety of an IDH1 inhibitor and hypomethylating agent in advanced AML shows success.
This new indication for the injection alkylating agent pertains to adult or pediatric patients aged one year and older.
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
In a phase 1 trial presented at ASH 2024, clinical benefit was observed in 100% of patients receiving LYT-200 monotherapy.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Quizartinib is a novel, second-generation, selective type II FLT3 inhibitor approved in the US for FLT3-ITD–positive AML.
QuANTUM-Wild has begun treatment administration in patients with newly-diagnosed FLT3-ITD+ AML.
Moderated by Amer M. Zeidan, MBBS, a panel discusses the critical roles of patient fitness, genetics in AML treatment.
This expert panel shares insights into the latest advancements, clinical challenges in AML and more.
Gain valuable insights from leading experts as they explore how targeted therapies are shaping the future of AML management.
Investigators looked into how intensified induction therapy impacts survival and MRD negativity in patients with AML.
Results from the phase I/II SAVE study in older and unfit patients with relapsed or refractory acute myeloid leukemia.
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Advertisement
Latest News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.